Venu G Pillarisetty MD
Pancreas, Minimally Invasive Surgery
Professor, Surgery, University of Washington School of Medicine; Associate Medical Director of Surgical Oncology, Fred Hutch Cancer Center and University of Washington Medical Center
Join to View Full Profile
1959 NE Pacific StBox 356410Seattle, WA 98195
Phone+1 206-616-4924
Dr. Pillarisetty is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Venu Pillarisetty is a sugical oncologist based in Seattle, WA, with subspecialties in pancreas and minimally invasive surgery. Dr. Pillarisetty completed surgical residency at UMass Chan Medical School and a fellowship in complex general surgical oncology at Memorial Sloan Kettering Cancer Center. Current roles include Associate Medical Director and Professor at the University of Washington School of Medicine. With extensive experience in pancreatic cancer, immunotherapy, and minimally invasive procedures, Dr. Pillarisetty has published on topics like antitumor immunity and pancreatic fistula prevention. Involved in clinical trials, notably a Phase II trial of Lanreotide for pancreatic fistula prevention, Dr. Pillarisetty has received recognitions such as Top Doctors from Seattle Metropolitan Magazine and is a Fellow of the American College of Surgeons.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Complex General Surgical Oncology, 2007 - 2009
UMass Chan Medical SchoolResidency, Surgery, 1999 - 2007
Columbia University Vagelos College of Physicians and SurgeonsClass of 1999
Certifications & Licensure
WA State Medical License 2009 - 2028
ID State Medical License 2023 - 2026
American Board of Surgery Surgery
Awards, Honors, & Recognition
- Top Doctors Seattle Metropolitan Magazine
- Fellow American College of Surgeons
Clinical Trials
- A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula Start of enrollment: 2018 Feb 20
Publications & Presentations
PubMed
- Overcoming CXCR4-Mediated T-Cell Exclusion Potentiates Antitumor Cytotoxicity in Fibrolamellar Carcinoma.Jason A Carter, Lindsay K Dickerson, Andreas Stephanou, Sheela R Damle, Kristin E Goodsell
Gastroenterology. 2026-04-01 - 1 citationsIntratumoral Three-Cell-Type Clusters Are a Conserved Feature of Endogenous Antitumor Immunity.Sheela R Damle, Jason A Carter, Kristin E Goodsell, Jose M B Pineda, Lindsay K Dickerson
Cancer Immunology Research. 2026-02-03 - Neoadjuvant therapy-induced remodeling of tumor immune microenvironment in pancreatic ductal adenocarcinoma: a spatial and digital pathology analysis.Danting Li, Yongjun Liu, Ruoxin Lan, Venu G Pillarisetty, Xiaofei Zhang
Virchows Archiv. 2026-02-01
Press Mentions
BBI Funds Immunotherapy Research to Help Address Pancreatic and Kidney Cancers, a Project That ‘Exemplifies Precision Medicine’April 12th, 2022
To Operate or Not? Navigating Gray Areas in Surgical OncologyJanuary 17th, 2020
Professional Memberships
- Fellow
- Member
- American Association for Cancer ResearchMember
- Society of University SurgeonsMember
Industry Relationships
- Member of Scientific Advisory Board, TriSalus Life Sciences2022 - Present
External Links
- Lab websitehttps://uwtimelab.com/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
